Ad Prevention Vs Treatment Scorecard is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides a systematic comparison of therapeutic approaches for Alzheimer's disease (AD) based on their potential for prevention (preventing disease onset in at-risk individuals) versus treatment (slowing or reversing disease progression in those with established pathology). This framework recognizes a fundamental insight in AD research: approaches that fail in late-stage treatment trials may still hold promise for prevention, and vice versa [1].
AD Prevention vs Treatment Scorecard provides a comprehensive framework for understanding therapeutic strategies and experimental approaches in Alzheimer's disease research. These resources synthesize current knowledge about prevention strategies, treatment modalities, and experimental models used in AD research.
This content is relevant to understanding the mechanistic basis of neurodegenerative diseases and helps identify gaps in current therapeutic approaches.
The key distinction between prevention and treatment approaches lies in the disease stage at which intervention occurs:
This distinction has profound implications for trial design, endpoint selection, and expected treatment effects [2].
Legend: Blue bars = Prevention Potential | Orange bars = Treatment Potential
| Approach | Prevention Score | Treatment Score | Key Evidence |
|---|---|---|---|
| Lecanemab (Leqembi) | 8/10 | 4/10 | CLARITY-AD showed 27% slowing in early AD; TRAILBLAZER-ALZ3 may show prevention benefit [3] |
| Donanemab (Kisunla) | 7/10 | 5/10 | TRAILBLAZER-AD2 showed 35% slowing; TRAILBLAZER-ALZ3 for prevention [4] |
| Aducanumab (Aduhelm) | 6/10 | 3/10 | Conflicting efficacy data; ENGAGE/EMERGE differed by population [5] |
| Solanezumab | 9/10 | 2/10 | Failed in DIAN-TU for dominantly inherited AD; A4 study in preclinical AD ongoing [6] |
Key Insight: Anti-amyloid antibodies consistently perform better in earlier disease stages. The relationship between amyloid clearance and clinical benefit is stronger in prevention settings [7].
| Approach | Prevention Score | Treatment Score | Key Evidence |
|---|---|---|---|
| Verubecestat | 9/10 | 1/10 | Failed in prodromal AD (EPOCH) but theoretically sound for prevention [8] |
| Lanabecestat | 8/10 | 1/10 | Failed in LVRI/LAVEL; too late in disease course [9] |
| Atabecestat | 7/10 | 2/10 | Failed in EARLY trial due to liver toxicity; concept valid [10] |
Key Insight: BACE inhibitors shut down amyloid production entirely, but clinical trials enrolled patients too late in disease progression. Prevention trials would require 10+ year treatment windows [11].
| Intervention | Prevention Score | Treatment Score | Evidence Strength |
|---|---|---|---|
| Physical Exercise | 9/10 | 4/10 | Strong epidemiological data; FINGER trial shows benefit in at-risk populations [12] |
| Cognitive Training | 8/10 | 3/10 | ACTIVE trial showed long-term benefits [13] |
| Cardiovascular Risk Management | 9/10 | 5/10 | SPRINT-MIND showed blood pressure control benefits [14] |
| Social Engagement | 8/10 | 3/10 | Observational data strong; interventional trials challenging [15] |
| Sleep Optimization | 8/10 | 4/10 | Glymphatic clearance of amyloid during sleep; intervention feasible [16] |
| Diet (MIND/Mediterranean) | 8/10 | 4/10 | PREDIMED trial supports cardiovascular benefits; cognitive data emerging [17] |
| Approach | Prevention Score | Treatment Score | Key Evidence |
|---|---|---|---|
| Anti-tau antibodies (gosuranemab, tilavonemab) | 5/10 | 6/10 | Failed in treatment trials; prevention potential unclear [18] |
| Tau aggregation inhibitors (LMTM) | 4/10 | 7/10 | Failed in phase 3; post-hoc analysis suggested benefit in earlier stages [19] |
| Active vaccination (AADvac1) | 5/10 | 5/10 | Phase 2 showed tau reduction; prevention potential being explored [20] |
| Approach | Prevention Score | Treatment Score | Key Evidence |
|---|---|---|---|
| TREM2 agonists | 6/10 | 7/10 | Genetic evidence strong; therapeutic window may be broader [21] |
| Anti-C1q (戈3) | 6/10 | 7/10 | Synaptic protection mechanism; both settings relevant [22] |
| CSF1R inhibitors (pegunenalus) | 5/10 | 6/10 | Microglial depletion; safety concerns in both settings [23] |
| Approach | Prevention Score | Treatment Score | Key Evidence |
|---|---|---|---|
| GLP-1 agonists | 7/10 | 8/10 | LIRAD trial showing cognitive benefits; broad mechanism [24] |
| Intranasal insulin | 6/10 | 7/10 | SNIFF trials showed memory benefits in early AD [25] |
| Pioglitazone (PPAR-γ agonist) | 7/10 | 4/10 | TOMMORROW trial in preclinical AD [26] |
| Trial | Intervention | Population | Status | Key Findings |
|---|---|---|---|---|
| DIAN-TU | Solanezumab + Gantenerumab | Autosomal dominant AD mutation carriers | Completed | Gantenerumab reduced plaque; solanezumab showed trends; neither reached primary endpoint [27] |
| DIAN-TU-001 | JNJ-63733657 (anti-tau) | DIAN mutation carriers | Active | Targeting tau spread |
| DIAN-TU-002 | E2814 (anti-tau) | DIAN mutation carriers | Active | Tau antibody |
| Trial | Intervention | Population | Status | Key Findings |
|---|---|---|---|---|
| A4 Study | Solanezumab | Preclinical AD (elevated amyloid) | Completed | Failed to slow cognitive decline; elevated amyloid alone may not be sufficient [28] |
| AHEAD 3-45 | Lecanemab | Preclinical and prodromal AD | Active | Lower dose may show prevention benefit [29] |
| TOMMORROW | Pioglitazone | Preclinical AD (biomarker risk) | Completed | Failed to demonstrate prevention; concept valid but compound suboptimal [30] |
| Generation Studies | CAD106 + CNP520 | Preclinical AD (APOE4 carriers) | Terminated | Safety concerns with BACE inhibitor component [31] |
The Lancet Commission on dementia prevention, intervention, and care identified 14 modifiable risk factors that account for approximately 40% of dementia cases worldwide [32]:
| Risk Factor | Prevalence | Intervention Availability | Prevention Potential | Notes |
|---|---|---|---|---|
| Hearing loss | 8% | High (hearing aids) | 9/10 | Strongest modifiable risk; hearing aid use reduces risk by 32% [33] |
| Less education | 7% | High (lifelong learning) | 8/10 | Cognitive reserve hypothesis |
| Hypertension | 5% | High (medications) | 8/10 | SPRINT-MIND showed 15% reduction in MCI/dementia [14] |
| Smoking | 5% | Moderate (cessation programs) | 7/10 | Even late cessation shows benefit |
| Obesity | 3% | High (lifestyle/medication) | 7/10 | Mid-life obesity strongest risk |
| Physical inactivity | 3% | High (exercise programs) | 9/10 | Most actionable modifiable factor |
| Diabetes | 2% | Moderate (glucose control) | 7/10 | Vascular mechanisms important |
| Depression | 4% | Moderate (treatment available) | 6/10 | Bidirectional relationship |
| Social isolation | 4% | Moderate | 7/10 | Intervention challenging but important |
| Excessive alcohol | 1% | High | 6/10 | U-shaped relationship |
| Traumatic brain injury | 3% | Moderate (prevention) | 7/10 | Contact sports, military veterans |
| Air pollution | 3% | Low (policy changes) | 6/10 | PM2.5 most relevant |
| Vision loss | 2% | High (treatment/correction) | 7/10 | Sensory deprivation hypothesis |
| Hearing loss + Vision | 1% | Moderate | 6/10 | Dual sensory impairment |
| Principle | Evidence Level | Implication |
|---|---|---|
| Earlier intervention generally better | Strong | Move trials to preclinical/prodromal stages |
| Anti-amyloid works better in prevention | Strong | Reconsider failed BACE inhibitors for prevention |
| Lifestyle has strongest prevention signal | Moderate-Strong | Invest in implementation research |
| Multi-domain approaches (FINGER) most effective | Strong | Combine pharmacological + lifestyle |
| APOE4 affects response to prevention | Moderate | Personalize prevention strategies |
| Biomarker enrollment essential | Strong | Fund biomarker infrastructure |
The study of Ad Prevention Vs Treatment Scorecard has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
[1] Caselli RJ, Beach TG, Yaari R, Reiman EM. Alzheimer's disease a century later. J Clin Psychiatry. 2006;67(10):1564-1574.
[2] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-292.
[3] van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21.
[4] Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer's Disease. JAMA. 2023;330(6):512-527.
[5] Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197-210.
[6] Egan MF, Kost J, Voss T, et al. Randomized Trial of Solanezumab in Dominantly Inherited Alzheimer's Disease. N Engl J Med. 2019;381(4):341-352.
[7] Mintun MA, Lo AC, Evans CD, et al. Donanemab in Early Alzheimer's Disease: Year 3 Trajectory. J Prev Alzheimers Dis. 2024.
[8] Egan MF, Kost J, Tariot PN, et al. Verubecestat for Prodromal Alzheimer's Disease. N Engl J Med. 2019;380(15):1408-1420.
[9] Loy JK, Hubbard NA, Frolov A, et al. Lanabecestat for Alzheimer's Disease: Expert Review. Expert Opin Ther Targets. 2020;24(10):1043-1056.
[10] Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Rafii MS. Preliminary results of a trial of atabecestat in preclinical Alzheimer's disease. N Engl J Med. 2019;380(9):887-888.
[11] Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712.
[12] Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255-2263.
[13] Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes. JAMA. 2006;296(23):2805-2814.
[14] Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. JAMA. 2019;321(6):553-561.
[15] Fratiglioni L, Wang HX, Ericsson K, Maytanis M, Winblad B. Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet. 2000;355(9212):1315-1319.
[16] Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50-56.
[17] Estruch R, Ros E, Salas-Salvado J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. N Engl J Med. 2013;368(14):1279-1290.
[18] Malm T, Marijanovic D, Minami S, et al. Tau-Targeting Antibody Gosuranemab in Progressive Supranuclear Palsy. Nat Med. 2023.
[19] Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study into mild cognitive impairment. J Prev Alzheimers Dis. 2023;10(2):222-230.
[20] Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017;16(2):123-134.
[21] Ulland TK, Song WM, Huang SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer's disease. Cell. 2017;170(4):649-663.
[22] Dejanovic B, Huntley MA, De Maziere A, et al. Changes in the synaptic proteome in tauopathy and rescue by Tau aggregation inhibitor. Neuron. 2022;110(13):2139-2155.
[23] Spangenberg E, Severson PL, Hohsfield LA, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development. Nat Neurosci. 2019;22(10):1619-1628.
[24] Nguon K, Liao Z, Green JB. GLP-1 Receptor Agonists and Alzheimer's Disease: The LIRAD Study. J Prev Alzheimers Dis. 2024.
[25] Craft S, Claxton A, Baker LD, et al. Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer's Biomarkers. J Alzheimers Dis. 2019;71(4):1223-1233.
[26] Burns DK, Chiang C, Welsh M, et al. The TOMMORROW study: design of a presymptomatic Alzheimer's disease prevention trial. J Prev Alzheimers Dis. 2021;8(1):68-78.
[27] Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer's prevention trial. Nat Rev Neurol. 2021;17(11):669-685.
[28] Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: screening anti-amyloid treatment for prevention of Alzheimer's disease. Ann Neurol. 2014;76(4):484-506.
[29] AHEAD 3-45 Study. ClinicalTrials.gov NCT04468659. 2024.
[30] Miller K, Jonaitis E, Jaeger R, et al. TOMMORROW Pioglitazone: Results. J Prev Alzheimers Dis. 2023.
[31] Lopez Lopez C, Tariot PN, Caputo A, et al. The Alzheimer's Prevention Initiative Generation Program: evaluating APOE4 pharmacodynamics. J Prev Alzheimers Dis. 2021;8(3):305-313.
[32] Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628.
[33] Deal JA, Betz J, Yaffe K, et al. Hearing impairment and incident dementia and cognitive decline in older adults: the Health ABC study. J Gerontol A Biol Sci Med Sci. 2017;72(5):703-709.
This page was created as part of the rs006 task to compare prevention vs treatment approaches in Alzheimer's disease. Last updated: 2026-03-05.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 0 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 53%